Daniel Moreno De Luca

Dr. Daniel Moreno De Luca

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
DLDaniel Moreno De Luca
Daniel Moreno De Luca
CMChrista Lese Martin
Christa Lese Martin

10 February 2022 in Genes
Verified
Journal Article
Open access
PDF file
Merlin ButlerMerlin Butler
Merlin Butler
DLDaniel Moreno De Luca
Daniel Moreno De Luca
APAntonio M. Persico
Antonio M. Persico
In clinical settings, the information provided by genetic testing can explain the triggers and processes underlying clinical presentations, such as neurodevelopmental disorders, in up to one third of affected individuals. However, translating this knowledge into better and more personalized clinical management to many appears a distant target. This article presents three paradigmatic cases to exemplify how this translational effort can, at least in some instances, be undertaken today with very positive results: (a) a young girl carrying a chr. 16p11.2 duplication can be screened using targeted exams and undertake therapeutic/preventive interventions related to her genetic diagnosis; (b) a 13-year-old boy with intellectual disability and autism spectrum disorder carries a chr. 11q14.1 deletion, partly spanning the DLG2 gene important for synaptic function, and gained over 20 I.Q. points ostensibly due to carbolithium, prescribed in the absence of affective symptoms, exclusively following the pathophysiology pointed out by the genetic results; (c) a 58-year-old woman carries a COL3A1 gene variant responsible for the vascular form of Ehler–Danlos syndrome with colon rupture. Detection of this variant in six members of her extended family allows for better clinical management of the proband and targeted genetic counselling for family members at risk of this connective tissue disorder. The unprecedented flow of genetic information available today through new technologies, if interpreted in the light of current knowledge in clinical diagnosis and care of those with connective tissue disorders and neurodevelopmental disturbances, in biology and in neuropsychopharmacology, can promote better clinical and pharmacological treatment, disease surveillance, and management provided and incorporated into the clinical setting.

1 April 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
PDF file
DLDaniel Moreno De Luca
Daniel Moreno De Luca
MRMichael E. Ross
Michael E. Ross
DRDavid A. Ross
David A. Ross

1 April 2019 in Biological Psychiatry
Verified
Journal Article
Closed access
JGJonathan Goldstein
Jonathan Goldstein
DRDavid A. Ross
David A. Ross
DLDaniel Moreno De Luca
Daniel Moreno De Luca

27 October 2020
Verified
Journal Article
Closed access
DLDaniel Moreno De Luca
Daniel Moreno De Luca

25 May 2023 in Academic Psychiatry
Verified
Journal Article
Closed access
PDF file
JKJulia Katz
Julia Katz
JHJeffrey Hunt
Jeffrey Hunt
KCKaren Cammuso
Karen Cammuso
DLDaniel Moreno De Luca
Daniel Moreno De Luca